Dicot AB
Dicot Pharma AB engages in the development of pharmaceutical products in Sweden. It develops LIB-01 for the treatment of erectile dysfunction and premature ejaculation. The company was formerly known as Dicot AB (publ) and changed its name to Dicot Pharma AB in May 2024. Dicot Pharma AB was incorporated in 2015 and is based in Uppsala, Sweden.
Dicot AB (DICOT) - Net Assets
Latest net assets as of December 2025: Skr73.40 Million SEK
Based on the latest financial reports, Dicot AB (DICOT) has net assets worth Skr73.40 Million SEK as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr85.50 Million) and total liabilities (Skr12.10 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr73.40 Million |
| % of Total Assets | 85.85% |
| Annual Growth Rate | 26.85% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 322.22 |
Dicot AB - Net Assets Trend (2021–2025)
This chart illustrates how Dicot AB's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Dicot AB (2021–2025)
The table below shows the annual net assets of Dicot AB from 2021 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | Skr73.40 Million | -34.27% |
| 2024-12-31 | Skr111.67 Million | +151.54% |
| 2023-12-31 | Skr44.39 Million | +728.55% |
| 2022-12-31 | Skr5.36 Million | -81.10% |
| 2021-12-31 | Skr28.35 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Dicot AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 6617870000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | Skr73.40 Million | 100.00% |
| Total Equity | Skr73.40 Million | 100.00% |
Dicot AB Competitors by Market Cap
The table below lists competitors of Dicot AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
SPARQ Corp.
OTCQB:SPRQF
|
$55.18 Million |
|
The BORN Korea
KO:475560
|
$55.19 Million |
|
SDCL EDGE Acquisition Corporation
NYSE:SEDA-UN
|
$55.19 Million |
|
POLARIS MEDIA ASA NK 20
F:93J
|
$55.20 Million |
|
SKY Metals Ltd
AU:SKY
|
$55.16 Million |
|
Bonraybio Co., Ltd.
TW:6955
|
$55.16 Million |
|
Sriracha Construction Public Company Limited
BK:SRICHA
|
$55.15 Million |
|
Surrozen Inc
NASDAQ:SRZN
|
$55.14 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Dicot AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 111,667,000 to 73,400,000, a change of -38,267,000 (-34.3%).
- Net loss of 80,200,000 reduced equity.
- New share issuances of 43,800,000 increased equity.
- Other factors decreased equity by 1,867,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-80.20 Million | -109.26% |
| Share Issuances | Skr43.80 Million | +59.67% |
| Other Changes | Skr-1.87 Million | -2.54% |
| Total Change | Skr- | -34.27% |
Book Value vs Market Value Analysis
This analysis compares Dicot AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 9.83x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 2.67x to 9.83x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | Skr0.13 | Skr0.36 | x |
| 2022-12-31 | Skr0.02 | Skr0.36 | x |
| 2023-12-31 | Skr0.04 | Skr0.36 | x |
| 2024-12-31 | Skr0.06 | Skr0.36 | x |
| 2025-12-31 | Skr0.04 | Skr0.36 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Dicot AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -109.26%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.16x
- Recent ROE (-109.26%) is above the historical average (-189.79%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -95.85% | 0.00% | 0.00x | 1.12x | Skr-30.01 Million |
| 2022 | -592.69% | 0.00% | 0.00x | 2.31x | Skr-32.29 Million |
| 2023 | -99.47% | 0.00% | 0.00x | 1.21x | Skr-48.60 Million |
| 2024 | -51.67% | 0.00% | 0.00x | 1.11x | Skr-68.87 Million |
| 2025 | -109.26% | 0.00% | 0.00x | 1.16x | Skr-87.54 Million |
Industry Comparison
This section compares Dicot AB's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $97,314,491
- Average return on equity (ROE) among peers: -50.89%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Dicot AB (DICOT) | Skr73.40 Million | -95.85% | 0.16x | $55.17 Million |
| BioGaia AB (publ) (BIOG-B) | $230.35 Million | 33.15% | 0.21x | $714.80 Million |
| Enzymatica publ AB (ENZY) | $76.61 Million | -64.91% | 0.64x | $20.94 Million |
| Enorama Pharma AB (ERMA) | $17.02 Million | -96.01% | 1.28x | $566.46K |
| Gabather AB (publ) (GABA) | $10.96 Million | -155.04% | 0.40x | $732.74K |
| Klaria Pharma Holding AB (KLAR) | $-452.69K | 0.00% | 0.00x | $15.08 Million |
| Moberg Pharma AB (publ) (MOB) | $76.79 Million | -8.31% | 0.20x | $38.42 Million |
| Nanexa AB (NANEXA) | $101.53 Million | -11.22% | 0.36x | $39.92 Million |
| Newbury Pharmaceuticals AB (NEWBRY) | $51.92 Million | -29.67% | 0.75x | $559.69K |
| Orexo AB (ORX) | $311.10 Million | -126.01% | 0.76x | $45.88 Million |